The future is looking promising for businesses hoping to tap into the growing CBD and wellness space.
The global market for cannabidiol (CBD), valued at $9.3bn1 in 2020, is forecasted to reach $23.6bn in revenue by 2025. With an expected compound annual growth rate of 22.2% from 2019 to 2025, the future is looking incredibly promising for businesses tapping into CBD’s explosive popularity.
North America continues to lead the market with 40% of the global CBD market share2, but it may not dominate for long. Europe is closing
With a 31 percent market share, it is expected3 to overtake North America in terms of regional demand.
The Valens Company is ideally positioned to address the world demand for CBD as a world leader in end-to-end development and manufacture of new cannabinoid-based products. Valens is the CBD wellness industry’s preferred partner since it provides specialized services ranging from plant processing and extraction to product creation, analytical testing, and white labeling.
CBD is legal in Europe.
In Europe, the legality of cannabis varies by country, with several only allowing medicinal usage. Hemp-derived CBD products for recreational use have been widely legalized, however some technically operate in a legal gray area due to differing definitions of what qualifies a plant as hemp. Product quality, consistency, and regulation issues have stifled industry expansion and jeopardized customer safety.
The CBD industry in Europe is loaded with promise, with an estimated value of €1.5 billion4 by 20235. The Court of Justice of the European Union concluded in November 20206 that CBD is not a narcotic, enabling it to be freely marketed throughout the European Union. This decision has paved the way for a clearer regulatory road for the legal use of CBD, favoring enterprises who produce high-quality CBD products.
Valens is actively involved in the creation of wellness-focused product solutions, looking beyond the market for typical CBD-forward cannabis products. By 2028, CBD products are expected to account for more than 0.15 percent of the entire health and wellness industry. Valens hopes to work with businesses to appeal to a new group of customers who have never tried cannabis: with to technology improvements and product innovation, CBD’s potential for integration into the wellness category is virtually endless.
Overview of CBD products
Imitations and fraudulent product claims weaken the market potential for enterprises focused on quality, while laws lags behind customer demand. Many people are interested in CBD, but are unsure how to choose the best product for them since they are inexperienced with the industry. Consumer education and quality assurance are critical for firms investing in high-quality, compliant CBD products.
What’s the deal with CBD?
Over 120 phytocannabinoids8, plant chemicals with the capacity to activate receptors in the endocannabinoid system, are found in cannabis (Cannabis sativa, L.). THC and CBD are the most widely used and researched cannabinoids, although research into the medicinal potential of numerous lesser-known cannabinoids such cannabichromene (CBC) and cannabinol is underway (CBN). CBD continues to stand out in terms of its medicinal potential from a wellness standpoint.
Potential health advantages
CBD appears to provide a variety of possible health advantages, according to a number of preliminary research studies. The recent European Court of Justice decision designating CBD as a non-narcotic offers up new prospects for more comprehensive study.
Epidyolex®10, which is used as an additional therapy for seizures associated with Lennox-Gastaut and Dravet syndromes, is presently the only CBD-containing pharmaceutical product licensed for use in the EU. Meanwhile, CBD has grown in popularity in the wellness sector as a result of its potential for pain relief11, relaxation12, and inflammation relief13.
Hemp seed oil and CBD oil
Hemp seed oil and CBD oil are both non-intoxicating oils derived from the cannabis plant. They are, nevertheless, extremely distinct products in terms of both development and marketing.
Hemp seed oil14 is made only from hemp seeds and is extracted by cold pressing. Hemp seeds are not a known source of CBD since they contain little or no cannabinoids. Hemp seed oil, which is high in omega-3 and omega-6 fatty acids, can give a variety of nutritional advantages when consumed. It may also be used topically to dry skin to alleviate it15.
CBD oil, also known as hemp extract, is extracted from the cannabis plant using a solvent such as CO2 or ethanol. CBD can be obtained from the plant’s flowering heads or taken from the whole plant.
Some companies claim that hemp seed oil products have the same potential health advantages as CBD. The distinctions between these two items will be made visible to customers through increased customer education and awareness, as well as regulatory guidance for wellness product labeling and testing.
CBD obtained from hemp vs. CBD derived from cannabis
Another point of contention in CBD is the origin of the plant. Hemp and drug-type cannabis come from the same plant species, Cannabis sativa L. Any cannabis plant that has more than 0.2 percent THC (on a dry weight basis) is classified as drug-type cannabis in Europe. Hemp is defined as anything that falls below that threshold.
Because the resin16 released by cannabis plants maintains stable cannabinoid ratios, drug-type cannabis generates proportionately more CBD than hemp by volume, despite its greater THC content. CBD is constant at the molecular level, regardless of the plant source.
Concentrations of CBD
Many marijuana products’ marketed CBD content does not match their actual measured CBD content since rigorous testing is not required. For example, a study17 of 29 over-the-counter CBD products in the United Kingdom discovered that the majority of the items tested (62%) did not contain CBD levels within 10% of the quantity specified on the label. This research validates prior comparative studies18 on labelling inaccuracy, with findings ranging from 0% to 155% of what was on the product label.
CBD is thought to have a minimal misuse potential19 and no major negative effects20 at greater dosages, thus product mislabeling isn’t always a sign of danger. Mislabeled goods, on the other hand, can lead to inefficacy and bad experiences, lowering customer perceptions of CBD’s potential advantages. Validated potency testing and precise labeling are thus critical for establishing customer trust.
Processing and extraction
The technique of extraction and amount of processing necessary to make CBD for use as an ingredient are determined by the intended end-product. Valens provides a broad range of patented extraction services, including CO2, ethanol, hydrocarbon, solvent-free, and terpene extraction, to fulfill fluctuating demand.
Initial extractions often yield an oleoresin high in cannabinoids and terpenes. Before being considered an ingredient, this extract must be winterized to remove impurities (waxes and lipids), and additional purification can be done if required to eliminate terpenes and cannabinoids other than CBD. The winterized resin, for example, can be distilled to make a purified CBD distillate free of terpenes, or refined further using crystallization or chromatography to generate a CBD isolate that is 99 percent pure CBD and free of other cannabinoids. Depending on the type of completed product and desired features, different purities of extract are utilized.
CBD isolates and oils
The need for edible oils has hitherto dominated the CBD industry. As a result of processing, there are some significant changes in the composition of different oils:
Full spectrum CBD: the most similar to the original material in terms of composition, this product comprises cannabinoids, flavonoids, and terpenes, and if THC is present in the beginning material, it will also be present in the finished product.
CBD oil with a broad spectrum — this type of oil is made in the same way as full spectrum oil, but without the THC.
Distillates of CBD: Distillates are high-potency distilled CBD that has been refined to eliminate flavor and odor — they are commonly used in vaporiser cartridges, edibles, and topicals.
CBD isolates are CBD in its purest form, usually in the form of a powder or crystal.
CBD incorporation into other goods
Miscibility is one of the challenges in using CBD oil into wellness goods: incorporating an oil-based component into products that are typically water-based poses an issue of product separation. This can lead to inconsistencies in dose and erroneous labeling if not carefully handled.
Rather than resolving the challenge of combining oil and water, Valens came up with a solution: an enlarged license to create and market goods based on SRSETM technology. Valens provides European partners with the capacity to convert any CBD oil into a water-soluble emulsion in foreign markets.
Technology based on emulsion
A stable combination of oil-soluble (CBD) and water-soluble substances is known as an emulsion. SRSE by Valens is a shelf-stable emulsion technology that has been proven to last up to 12 months. SRSE eliminates product variability through reproducible design, resulting in uniform CBD emulsions. Valens’ SRSE-based products are immune to common problems about product separation, such as creaming, clarity, and/or sedimentation.
SRSE by Valens, which is available in liquid, normal powder, and agglomerated powder forms, allows CBD to be seamlessly integrated into nearly any product. It is fully configurable and enables for the creation of one-of-a-kind product-specific formulas. Consumer-pleasing flavors and smells can be achieved with a minimum sensory effect.
Products that are easily digestible
The market for CBD consumables21 is rapidly increasing, with products ranging from CBD gummies, brownies, and chocolates to drinks and gel-capsule supplements. Valens’ SRSE-based products are immune to common problems about product separation, such as creaming, clarity, and/or sedimentation. By utilizing Valens’ SRSE technology,